Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
1986 1
1988 1
1989 2
1992 1
1993 1
1994 1
1996 2
1998 1
1999 1
2000 2
2001 2
2002 2
2003 2
2004 1
2005 1
2006 2
2008 2
2009 4
2010 2
2012 2
2013 2
2014 2
2015 3
2016 5
2017 3
2018 7
2019 8
2020 2
2021 2
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Breast Adenocarcinoma"
Page 1
Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease.
Hirai I, Tanese K, Nakamura Y, Ishii M, Kawakami Y, Funakoshi T. Hirai I, et al. Oncologist. 2019 Jun;24(6):e394-e396. doi: 10.1634/theoncologist.2018-0856. Epub 2019 Mar 7. Oncologist. 2019. PMID: 30846514 Free PMC article.
Extramammary Paget's disease (EMPD) is a rare cutaneous adenocarcinoma that clinicopathologically resembles breast cancer. The prognosis of metastatic EMPD is poor. ...When treating breast cancer, anthracycline is regarded as the key cytotoxic agent, and anth …
Extramammary Paget's disease (EMPD) is a rare cutaneous adenocarcinoma that clinicopathologically resembles breast cancer. The …
In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors.
Ni S, Li L, Sun X, Wang Y, Yu Q, Wang W, Gu Z, Yu Z, Wu D, Wu F, Jiang S, Peng P. Ni S, et al. Eur J Pharm Sci. 2024 Jan 1;192:106658. doi: 10.1016/j.ejps.2023.106658. Epub 2023 Dec 2. Eur J Pharm Sci. 2024. PMID: 38048851 Free article.
Early-stage clinical evaluation of tinengotinib (TT-00420) demonstrated encouraging preliminary efficacies in multiple types of refractory cancers, including fibroblast growth factor receptors (FGFR) inhibitors relapsed cholangiocarcinoma (CCA), castrate-resistant prostate …
Early-stage clinical evaluation of tinengotinib (TT-00420) demonstrated encouraging preliminary efficacies in multiple types of refractor …
Mechanisms of hormonal prevention of breast cancer.
Medina D, Sivaraman L, Hilsenbeck SG, Conneely O, Ginger M, Rosen J, Omalle BW. Medina D, et al. Ann N Y Acad Sci. 2001 Dec;952:23-35. doi: 10.1111/j.1749-6632.2001.tb02725.x. Ann N Y Acad Sci. 2001. PMID: 11795441 Review.
Reproductive history is a consistent risk factor for human breast cancer. Epidemiological studies have repeatedly demonstrated that early age of first pregnancy is a strong protective factor against breast cancer and provides a physiologically operative model to ach …
Reproductive history is a consistent risk factor for human breast cancer. Epidemiological studies have repeatedly demonstrated that e …
Benefits and risks of off-label olanzapine use for symptom management in cancer patients-a case report.
Dev R, Fortuno ES 3rd, Amaram-Davila JS, Haider A, Bruera E. Dev R, et al. Ann Palliat Med. 2023 May;12(3):600-606. doi: 10.21037/apm-22-1167. Epub 2023 Mar 14. Ann Palliat Med. 2023. PMID: 37038067 Free article.
CASE DESCRIPTION: Patient 1 is a female in her 70s with stage IV infiltrating ductal carcinoma of the right breast was having trouble tolerating treatment with letrozole, palbociclib, and denosumab due to uncontrolled nausea resulting in weight loss. Her nausea was refr …
CASE DESCRIPTION: Patient 1 is a female in her 70s with stage IV infiltrating ductal carcinoma of the right breast was having trouble …
Integrated analysis of single-cell and bulk RNA sequencing data reveals a myeloid cell-related regulon predicting neoadjuvant immunotherapy response across cancers.
Liu H, Sima X, Xiao B, Gulizeba H, Zhao S, Zhou T, Huang Y. Liu H, et al. J Transl Med. 2024 May 21;22(1):486. doi: 10.1186/s12967-024-05123-9. J Transl Med. 2024. PMID: 38773508 Free PMC article.
However, the majority of patients exhibit resistance or become refractory to immunotherapy, and the underlying mechanisms remain to be explored. ...A PPARG regulon (containing 23 target genes) was associated with ICI response, and its function was validated by a colorectal …
However, the majority of patients exhibit resistance or become refractory to immunotherapy, and the underlying mechanisms remain to b …
The concept of stem cell in the mammary gland and its implication in morphogenesis, cancer and prevention.
Russo J, Balogh GA, Chen J, Fernandez SV, Fernbaugh R, Heulings R, Mailo DA, Moral R, Russo PA, Sheriff F, Vanegas JE, Wang R, Russo IH. Russo J, et al. Front Biosci. 2006 Jan 1;11:151-72. doi: 10.2741/1788. Front Biosci. 2006. PMID: 16146722 Review.
The breast attains its maximum development during pregnancy and lactation. ...Based on these observations it was postulated that the Lobule type 1 found in the breast of nulliparous women and of parous women with breast cancer never went through the process o …
The breast attains its maximum development during pregnancy and lactation. ...Based on these observations it was postulated that the …
The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
Toda S, Iwasaki H, Okubo Y, Hayashi H, Kadoya M, Takahashi H, Yokose T, Hiroshima Y, Masudo K. Toda S, et al. Endocr J. 2024 Jan 29;71(1):31-37. doi: 10.1507/endocrj.EJ23-0342. Epub 2023 Dec 1. Endocr J. 2024. PMID: 38044137 Free article.
Of the 81 patients with differentiated thyroid carcinoma (DTC) and PDTC, 88.9% were radioactive iodine-refractory, and 32.7% of all cases had previously been treated with multiple kinase inhibitors. ...
Of the 81 patients with differentiated thyroid carcinoma (DTC) and PDTC, 88.9% were radioactive iodine-refractory, and 32.7% of all c …
Nanosomal Docetaxel Lipid Suspension: A Guide to Its Use in Cancer.
McKeage K. McKeage K. Clin Drug Investig. 2017 Apr;37(4):405-410. doi: 10.1007/s40261-017-0510-7. Clin Drug Investig. 2017. PMID: 28255844
Nanosomal docetaxel lipid suspension (NDLS) [DoceAqualip] is a novel formulation of docetaxel approved in India for the treatment of breast cancer, hormone-refractory prostate cancer, locally advanced squamous cell carcinoma of the head and neck, non-small cell lung …
Nanosomal docetaxel lipid suspension (NDLS) [DoceAqualip] is a novel formulation of docetaxel approved in India for the treatment of brea …
STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice.
Meyer-Losic F, Newman SP, Day JM, Reed MJ, Kasprzyk PG, Purohit A, Foster PA. Meyer-Losic F, et al. PLoS One. 2013 Dec 6;8(12):e80305. doi: 10.1371/journal.pone.0080305. eCollection 2013. PLoS One. 2013. PMID: 24324595 Free PMC article.
Despite paclitxael's clinical success, treating hormone-refractory breast cancer remains challenging. Paclitaxel has a poor pharmacological profile, characterized by a low therapeutic index (TIX) caused by severe dose limiting toxicities, such as neutropenia and per …
Despite paclitxael's clinical success, treating hormone-refractory breast cancer remains challenging. Paclitaxel has a poor ph …
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA. Tan WW, et al. Ann Oncol. 2010 Mar;21(3):493-497. doi: 10.1093/annonc/mdp328. Epub 2009 Jul 22. Ann Oncol. 2010. PMID: 19625343 Free PMC article. Clinical Trial.
BACKGROUND: Because of the single-agent activity of irinotecan hydrochloride, combination of irinotecan and docetaxel treatment against metastatic breast cancer (MBC) should be evaluated. PATIENTS AND METHODS: Single-stage phase 2 study of irinotecan and docetaxel to evalu …
BACKGROUND: Because of the single-agent activity of irinotecan hydrochloride, combination of irinotecan and docetaxel treatment against meta …
69 results